Aquestive Therapeutics Prices IPO

7/25/18

Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the pricing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $67,500,000. All of the shares in the offering are being offered by Aquestive Therapeutics. In addition, Aquestive Therapeutics granted the underwriters a 30-day option to purchase up to 675,000 additional shares of its common stock at the initial offering price, less underwriting discounts and commissions. Aquestive Therapeutics' common stock is expected to begin trading on the Nasdaq Global Market on July 25, 2018 under the ticker symbol "AQST."

BMO Capital Markets and RBC Capital Markets are acting as joint book-running managers for this offering. Wedbush PacGrow and JMP Securities are acting as co-lead managers for this offering.

About Aquestive Therapeutics

Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.